Bharat Biotech Vaccine
Fair Pharma Scorecard
Toetst farmaceutische bedrijven op mensenrechten.
Menu
Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
CanSino has not published a global access plan for its vaccine.
CanSino has not made a statement of commitment with human rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
CanSino has not committed to a responsible licensing mechanism such as C-TAP or the MPP.
CanSino has not committed to not enforcing the exclusive rights of Covid-19 patents.
CanSino has offered “tens of millions of doses” to Covax, but has to wait to receive WHO Emergency Use Listing before it can supply the mechanism with its vaccine.
CanSino has fill-and-finish sites in Pakistan, Malaysia and Mexico.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
Cansino has a technology transfer agreement with Pakistan.
CanSino prices its vaccine at 17 US dollars per dose to Argentina, and 27,15 per dose to the private market in Pakistan. It has also made a commitment to tiered pricing.
CanSino has so far sold doses to Mexico, Pakistan, Ecuador, Argentina, Malaysia, and Chile, which equates to almost 100% of its doses being sold to middle-income countries or high-income countries.
No information has been found on this criterion.
No information has been found on this criterion.
The company should be as transparent as possible, by publishing its research and development costs, profit margin, average costs of production, and production capacity for its Covid-19 product. It should also disclose the amount of public subsidies received during product development and/or testing. Licensing agreements should also be made publicly available and clinical trials should be registered in public repositories.
CanSino published its 3rd quarterly report Jan-Sep 2021 – its vaccine was authorised in February 2021 for general use (but was already used in China since June 2020). The research and development costs are published for this period, but are not specified for the vaccine.
CanSino has published its overall revenue, but not specific to the Covid-19 vaccine.
CanSino has not published the average and/or marginal costs of producing the vaccine.
CanSino plans to produce 500 million doses/year.
See Q3 2021 Financial report: ‘Government grants recognized though profit or loss for the current period excluding those closely related to the Company’s ordinary operations and granted on an ongoing basis under the national policies according to certain fixed quota of amount or volume’ = 2BN RMB = 314.529.44 US dollars.
CanSino has not published the texts of any licensing agreements.
CanSino has registered its clinical trials on clinicaltrials.gov.
Blijf op de hoogte van het werk van stichting Farma ter Verantwoording!
